Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28179999 | 0.80 | ERN1 (0.35) | ALOX15ALOX12ALDH1A1PRNPMAPT | |
| SCHEMBL7685032 | 0.80 | NQO2 (0.30) | — | |
| SCHEMBL748497 | 0.78 | CA2 (0.30) | CA2CA4 | |
| SCHEMBL29134461 | 0.78 | — | — | |
| SCHEMBL29134432 | 0.78 | — | — | |
| SCHEMBL9024081 | 0.72 | LMNA (0.41) | ALDH1A1MAPT | |
| SCHEMBL8622856 | 0.70 | ALOX5AP (0.31) | — | |
| SCHEMBL4439373 | 0.70 | AMY1A (0.33) | HSD17B10ALDH1A1PRNPMAPTNPSR1 | |
| SCHEMBL3410424 | 0.69 | S1PR1 (0.35) | HSD17B10ALDH1A1 | |
| SCHEMBL455314 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0549600-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1993-07-07 | — | — | EP | claimed |
| WO-1992005163-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1992-04-02 | — | — | WO | claimed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| US-6831081-B2 | Herpes virus including simplex types 1 and 2, varicella zoster, human cytomegalovirus, Epstein-Barr and human 6, 7 and 8 | PHARMACIA & UPJOHN | 2004-12-14 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040116464-A1 | Aryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004022568-A1 | ARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022566-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0549600-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992005163-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1992-04-02 | — | — | WO | disclosed |
| US-4274998-A | Diester of 3,5,3',5'-tetrabromo-bisphenol A with halogenated aromatic carboxylic acid | ASAHI-DOW LIMITED (JP) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110786-A1 | 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, MAVS | HSD17B10 3090/4885ALOX15 4183/4885ALOX12 4332/4885 |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | HSD17B10 3120/4885ALOX15 4832/4885ALOX12 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.